Results 91 to 100 of about 84,026 (244)

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi   +4 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya   +2 more
wiley   +1 more source

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs   +8 more
wiley   +1 more source

Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali   +14 more
wiley   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong   +2 more
wiley   +1 more source

Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyResearch in context

open access: yesThe Lancet Regional Health. Western Pacific
Summary: Background: Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies.
Xiaoling Cai   +14 more
doaj   +1 more source

Neurodevelopmental and Psychiatric Studies in Children and Adolescents With Neurofibromatosis Type I: A Comprehensive Scoping Review

open access: yesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, EarlyView.
ABSTRACT A comprehensive synthesis of the broad range of neurodevelopmental and psychiatric manifestations in NF1 is needed to identify knowledge gaps and future directions for NF1 research. In the following scoping review, we identify and summarize the scope of research that examines neurodevelopmental and psychiatric manifestations, both as ...
Meera Chopra   +5 more
wiley   +1 more source

The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen   +9 more
wiley   +1 more source

Appropriate Medical Therapy Primarily Modifies Type 2 and Severity Biomarkers in Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral ...
Asher C. Park   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy